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Abstract
Combining data from genome-wide association studies (GWAS) conducted at different locations, using genotype
imputation and fixed-effects meta-analysis, has been a powerful approach for dissecting complex disease genetics in
populations of European ancestry. Here we investigate the feasibility of applying the same approach in Africa, where
genetic diversity, both within and between populations, is far more extensive. We analyse genome-wide data from
approximately 5,000 individuals with severe malaria and 7,000 population controls from three different locations in Africa.
Our results show that the standard approach is well powered to detect known malaria susceptibility loci when sample sizes
are large, and that modern methods for association analysis can control the potential confounding effects of population
structure. We show that pattern of association around the haemoglobin S allele differs substantially across populations due
to differences in haplotype structure. Motivated by these observations we consider new approaches to association analysis
that might prove valuable for multicentre GWAS in Africa: we relax the assumptions of SNP–based fixed effect analysis; we
apply Bayesian approaches to allow for heterogeneity in the effect of an allele on risk across studies; and we introduce a
region-based test to allow for heterogeneity in the location of causal alleles.
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Introduction
Severe malaria, meaning life-threatening complications of
Plasmodium falciparum infection, kills on the order of a million
African children each year [1]. However this represents only a
small proportion of the total number of infected individuals, the
majority of whom recover without life-threatening complications.
Understanding the genetic basis of resistance to severe malaria
could provide valuable insights into molecular mechanisms of
pathogenesis and protective immunity that will aid the develop-
ment of treatments and vaccines. It might also identify selective
pressures that have shaped human physiology and susceptibility to
other common diseases, because of the historical impact of malaria
as a major cause of mortality in ancestral human populations.
Genome-wide association studies (GWAS) have identified
thousands of genetic variants which predispose individuals to
particular disease phenotypes. However, the vast majority of these
studies are of non-communicable disease in collections of
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individuals with European ancestry. The challenges of applying
these approaches to studying disease in Africa are well document-
ed [2]; the long ancestral history of African populations has two
consequences. Firstly it has led to an overall reduction in the
correlation (linkage disequilibrium) between alleles at neighbour-
ing loci. Secondly it has given rise to differences in the
combinations of alleles along chromosome (haplotypes) both
between, and within, geographically defined populations.
The first of these complications is problematic because GWAS
rely on the correlations between causal mutations and genotyped
markers to identify susceptibility variants. From a statistical
perspective, unless the causal marker is typed directly, the reduced
linkage disequilibrium acts to dilute association signals [3], making
it hard to distinguish real effects on disease risk from apparent
effects that arise from sampling. In theory this loss of power can be
overcome simply by increasing the sample size or the number of
typed markers [3]. Another way in which GWAS critically rely on
correlation among nearby variants is via imputation based meta-
analysis, which has proven a powerful tool for combining
information across collections of individuals with similar ancestry.
These approaches work by first obtaining genotypes at a common
set of loci and then combining the statistical evidence at each
locus, across collections, often by assuming the alleles to have a
consistent, or fixed, effect on susceptibility. However, the
differences in haplotype structure in Africa means that the
correlation between any given marker locus and the causal allele
may vary from one collection to the next, so the apparent effect on
risk may be heterogeneous. The utility of applying the same
methodology for meta-analysis in African populations is therefore
unclear.
Here we describe the first imputation based meta-analysis
approach in Africa to study severe malaria susceptibility across
multiple African populations. We use data from large samples of
individuals collected from Kenya, Malawi and Gambia which
together included 5425 individuals with severe malaria and 6891
population controls. As each of the collections was typed on a
different Illumina genotyping array, we used imputation (using the
program IMPUTE2 [4]) to obtain genotypes at a common set of
1.3 million SNPs. We use these data to investigate the accuracy of
the imputation, assess genetic structure within and between
populations, describe association patterns at loci known to
influence risk of severe malaria, and investigate methods for
identifying new susceptibility loci.
Results
Datasets and genotyping
MalariaGEN partners in Gambia, Malawi and Kenya collected
blood samples from children diagnosed with severe malaria,
including cerebral malaria and severe malarial anaemia. As
population controls, cord blood samples were collected from the
same geographic areas as the cases. Ethical approval was obtained
from each ethics committees at each of the partner study sites and
institutions (Table S1). DNA was extracted from the blood samples
and assayed at SNPs genome-wide on Illumina arrays. There are
challenges specific to collecting blood from children in Africa,
particularly if they are ill with severe malaria, making it hard to
obtain large quantities of DNA. We performed whole-genome
amplification (WGA) on a small quantity of DNA before array-
based genotyping to preserve samples. The process of WGA can
lead to additional experimental noise, potentially leading to
genotype calling errors. To produce a robust set of genotype
calls, we used three different calling algorithms to process intensity
data from the Illumina arrays, separately in each of the three
cohorts. A set of consensus calls was obtained by treating as
missing any genotype that was discordant among algorithms (see
Methods).
As high levels of missing (or discordant) genotypes are indicative
of poor genotype calling (either due to poor assay performance or
sporadic genotype clustering errors) we excluded SNPs with
.2.5% missing genotype calls. Using the three-way calling in this
way provided a robust set of SNPs for analysis and very little
additional filtering of SNPs was required (Table S3).
Prior to imputation we excluded samples with outlying levels of
missing or heterozygous genotypes as well as one of each pair of
duplicate samples (see Table S2). Preliminary analysis of the data
revealed a subset of control samples in the Malawi cohort which
showed sporadic assay failure at a small number of SNPs across
the genome. This type of error is hard to identify prior to analysis,
and we provide a description of our observations in Text S1 and
Figure S1 in case it is helpful to readers with similar data.
Imputation across African populations
Imputation is now a well-established strategy for exploiting
densely genotyped reference panels to infer genotypes at SNPs not
assayed directly in a given study. For each study collection we
thinned the set of SNPs to just those that passed quality control
filters and were present in the HapMap3 haplotype panel [5]
made available for use with the imputation program IMPUTE2
(http://mathgen.stats.ox.ac.uk/impute/impute_v2.html). We ran
IMPUTE2 separately on each collection using the entire
HapMap3 reference panel to obtain genotypes at a common set
of 1.3 million SNPs (see Methods).
The accuracy of the genotype imputation typically depends on
the correlation between typed and untyped SNPs and the
similarity of haplotypes in available reference panels to those in
the study samples. In both regards imputation in Africa is more
challenging than in non-African populations [6]. Our study
provides an opportunity to quantify the utility of imputation in this
setting, and illustrates a number of issues that are relevant to other
imputation-based studies in African populations.
We assessed the accuracy of imputation by comparing the
genotype calls obtained from the three-way calling described above
to the probabilistic estimates for those same SNPs produced by
IMPUTE2 (type 2 r2 in IMPUTE2). Figure 1 shows per-individual
Author Summary
Malaria kills nearly a million people every year, most of
whom are young children in Africa. The risk of developing
severe malaria is known to be affected by genetics, but so
far only a handful of genetic risk factors for malaria have
been identified. We studied over a million DNA variants in
over 5,000 individuals with severe malaria from the
Gambia, Malawi, and Kenya, and about 7,000 healthy
individuals from the same countries. Because the popula-
tions of Africa are far more genetically diverse than those
in Europe, it is necessary to use statistical models that can
account for both broad differences between countries and
subtler differences between ethnic groups within the same
community. We identified known associations at the genes
ABO (which affects blood type) and HBB (which causes
sickle cell disease), and showed that the latter is
heterogeneous across populations. We used these findings
to guide the development of statistical tests for association
that take this heterogeneity into account, by modelling
differences in the strength and genomic location of effect
across and within African populations.
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imputation accuracies broken down by country. While less accurate
than typically achieved using similar genotyping arrays in European
populations [7], imputation still captures the majority of common
variation in these three populations (a mean type 2 r2 of 0.93 in
Malawi, 0.92 in Kenya and 0.87 in Gambia). Common SNPs were
better imputed than low-frequency SNPs, suggesting that this
analysis, much like similar experiments in Europeans, will be
relatively less well powered to detect associations at low frequency
SNPs.
Two different types of inaccuracy are possible in imputed data:
overconfidence in predicting an incorrect genotype, or under-
confidence in predicting a correct genotype. We therefore
evaluated the calibration of the confidence of IMPUTE2
(measured by the info score) against its actual performance at
genotyped SNPs. The calibration of confidence was high across
our three samples (r2 between predicted and true accuracy: 0.93 in
Malawi, 0.92 in Kenya, 0.96 in Gambia) but, like overall accuracy,
on average worse than in European samples (0.96). Quality scores
were less well calibrated for low-frequency variation, but still
remained relatively high across all three populations (89%, 84%
and 92% respectively for variants with MAF,0.05). We included
only SNPs with info score.0.75 for downstream analyses, leaving
a high quality set with mean r2.0.9 in all samples, and less than
1% of either very overconfident (predicted r2.0.75, actual,0.6)
or very underconfident (predicted,0.75, actual.0.9) SNPs.
Taken together, these results suggest the underlying model of
IMPUTE2, combined with a diverse reference panel provided by
the HapMap project, is generally applicable to samples from
African populations.
Despite the high performance of imputation overall, there were a
number of factors that influenced relative imputation performance,
including (i) genotyping platform, (ii) ethnic matching of target
GWAS samples to the imputation reference panel, and (iii)
homogeneity of individual GWAS collections. Our Gambian
samples (typed on the Illumina 650Y array) show much poorer
imputation quality (Figure 1) than our Kenyan and Malawian
samples (typed on Illumina chips with .1 million SNPs). While
genotyping array represents the single most important factor to
imputation accuracy, two aspects of population genetics are also
critical: good matching between reference and target samples (here
achieved by using a cosmopolitan reference panel, likely to be
improved by future reference samples of African diversity [8]) and
homogeneity within a GWAS sample (illustrated by a small number
of samples of differential ancestry in Kenya with poorer imputation
quality, Figures S12 and S13).
Genetic structure within and between study samples
Genetic diversity in Africa is extensive [7] and our collections
derive from locations separated by thousands of miles and include
individuals from several distinct ethnic groups. To characterise
population structure we performed principal component analysis
(PCA) across our three African collections and a set of African
individuals genotyped as part of the HapMap 3 project. For this
purpose we selected a set of 121029 SNPs with accurate
(MAF.1%, IMPUTE2 info score.0.9) genotypes in all three
study collections, and then thinned the data to reduce the
correlation between neighbouring SNPs (see Methods).
To summarise the relatedness structure within our data, we
similarly produced a thinned list of SNPs with good calls separately
in each collection, and calculated allele sharing between all pairs of
individuals at the thinned set of SNPs. The distribution of the
degree of similarity between each individual and their closest
relative within each study is shown in Figure S2. High levels of
relatedness between individuals can violate the assumptions of
standard tests of association and can dominate attempts to
characterise population structure. For these reasons we iteratively
removed closely related individuals and those with atypical
ancestry as described in Methods. We refer to the remaining set
of individuals as the ‘‘filtered set’’ and use them for analyses which
rely on the use of principal components (PCs).
The projection of a subset of study and HapMap individuals
onto the first two PCs is shown in Figure 2. Some care is needed in
interpreting PCA of genetic data [9]; however, the analysis has the
property that the distance between any two individuals on the plot
is proportional to the genome-wide similarity in their genotypes.
The relationships among our samples broadly reflect the
geography and peopling of Africa; we see that East African study
samples from Kenya and Malawi cluster near one another and are
relatively close to HapMap Luhye individuals who are also from
Kenya (LWK); and the Gambian samples cluster closer to
Yoruban individuals from Nigeria (YRI), representing individuals
from West Africa. The Kenyan study samples are recruited from
the coastal region of Kilifi and our data confirm they are
genetically distinct from the Maasai (MKK).
To characterise the genetic diversity within collections we
performed PCA on each study separately and plotted all
individuals on the first two principal components (Figure 2). In
Gambia, the first PC separate the Fula from the rest of the sample
with subsequent PC (Figure S14) stratifying further ethnic groups,
as previously shown [10]. A similar relationship between genetic
diversity and self-reported ancestry is seen in Kenya.
Genome-wide meta-analysis
It is well known that subtle differences in the patterns of
relatedness between case and control individuals can potentially
Figure 1. Per-sample imputation accuracy measured by r2
between true genotypes and genotypes predicted by imputa-
tion, averaged over imputation chunks. Black vertical line shows
typical imputation accuracy in a UK population, taken from [8].
Gambian samples (red) perform worst due to the poor coverage of
African variation by the Illumina 550 K platform, followed by Kenyan
samples (green) on the Illumina Omni2.5M, which while dense has
limited overlap with our HapMap3 reference, with Malawian samples
(yellow) performing best. Note that imputation accuracy in the Kenyan
sample showed a bimodal distribution driven at least partially by ethnic
ancestry (Figures S12 and S13).
doi:10.1371/journal.pgen.1003509.g001
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lead to spurious signals of association [11]. We observed significant
correlation between case control status and the principal
components in each of studies (Table S4), and the probability
that the closest relative to each sample had the same case status
was significantly greater than an expected by chance (P,161024
in all three cohorts).
We took two approaches to controlling for the potential bias
that can result from population structure. Firstly we restricted
analysis to the filtered set described above and included five PCs as
covariates in a logistic regression analysis as implemented in the
program SNPTEST (https://mathgen.stats.ox.ac.uk/genetics_
software/snptest/snptest.html). Secondly we included all individ-
uals passing quality control filters by modelling the covariance in
case status due to relatedness between samples as a random effect
in a linear model approximation, as implemented in the program
MMM [12]. The latter of these approaches potentially retains
more power by increasing the sample size, and provides additional
robustness to population structure by modelling relatedness at all
levels (or equivalently using all PCs) [13]. Empirically, the
evidence for association at each SNP is similar between the two
methods (Figures S3 and S4) and both reduce the overall inflation
in test statistic to acceptable levels (Table S6). Throughout we
assume an additive model of association, estimating a single
parameter which determines the effect each copy of risk allele has
on the log-odds of being a case individual, using the mixed model
approach, unless otherwise stated.
To combine the evidence of association across studies we use an
inverse-variance weighted fixed effects approach to calculate an
estimate of the log of the odds ratio and its standard error
combined across the three studies [14]. This approach has become
the standard method for meta-analysis of case-control studies. We
return to a discussion of the meta-analysis below.
The results of the autosomal genome-wide association analysis
are shown in Figure S5. Two regions of the genome show
compelling evidence of association (P,561028). These include
SNPs near established malaria susceptibility loci; in the beta globin
(HBB) gene on chromosome 11 and in the ABO blood group gene
(ABO) on chromosome 9. Several other regions show strong but not
conclusive association (P,161026) and are detailed in Table S7.
Additional analysis using dominant, recessive or two-parameter
Figure 2. Principle components analysis. Top left: principal components analysis (PCA) of the African populations from Hapmap 3 (LWK= Luhya
in Webuye, Kenya, 90 individuals; MKK=Maasai in Kinyawa, Kenya, 143 individuals; YRI = Yoruba in Ibadan, Nigeria, 113 individuals) with 500
randomly selected control samples from each of the three study cohorts. Top right, bottom left, bottom right: PCA of all non-excluded samples in
each study cohort, coloured by reported ethnic group. Ethnic group is shown as ‘‘OTHER’’ for groups constituting less than 5% of individuals in the
cohort, or where the ethnic group was unreported.
doi:10.1371/journal.pgen.1003509.g002
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models did not reveal any other convincing regions of association
showing consistent evidence across collections, nor did direct
analysis of the genotype data (Figures S9 and S10).
Association at HBB and ABO
The strong signals of association at HBB and ABO demonstrate
that, despite the additional challenges of genetic analysis in Africa,
the standard approach to imputation based meta-analysis can
identify loci with convincing levels of evidence when sample sizes
are sufficiently large.
The non-synonymous variant rs334 in the HBB gene, whose
derived allele (HbS) causes sickle-cell anaemia in homozygote
individuals and is known to be strongly protective against malaria
in heterozygotes, is perhaps the best known case of balancing
selection in the genome [15]. The pattern of association around
this region across the three cohorts is shown in Figure 3. The SNP
rs334 is neither genotyped nor imputed in our genome-wide data.
In its absence, the strongest signal of association is seen over
400 kb upstream of HBB in the Kenya and Malawi studies. The
combined evidence at this locus drives the main fixed-effect meta-
analysis signal. Strikingly there is very little signal of association at
this position in the Gambian data, although strong evidence for
association is seen closer to HBB gene at 200 kb upstream and, to
a lesser extent, 200 kb downstream.
Direct genotyping of rs334 across the MalariaGEN data (see
Methods) allows us to measure the correlation (allelic r2, estimated
using EM algorithm) between the HbS allele and the SNPs around
HBB in our genome-wide data. The strength of the correlation is
indicated by the colour of the points in Figure 3. Association
analysis of the region including genotype at rs334 as a covariate
completely removes the signal (P.1024,see Figure S6). Together
these observations confirm that the heterogeneous signals of
association in the three cohorts are driven by their different
patterns of correlation with the causal allele rs334, probably
because it arose on different haplotypes in different ancestral
populations [16]. The lowest meta-analysis P value across the
region is at rs12788102 (P=1.9610216), which was imputed in
Gambia, whereas at the directly typed rs334 the meta-analysis
P=2.8e236. We note that the lowest SNPTEST meta-analysis P
value in this region is 5.7610213 at rs17325567.
In contrast to the complex patterns of association at HBB, the
strong meta-analysis evidence for association at ABO derives from
a combination of signals at the same set of SNPs across the three
cohorts (Figure 3). In each cohort the strength of association is
moderate with P.1e-6, so under the assumption that malaria
susceptibility loci of modest effect are rare in the genome, none of
these signals are convincing in any one study. However, when
combined via meta-analysis they reach established level of
significance (P,561028) for genome-wide analysis.
The determinants of the ABO blood group are SNPs within the
ABO gene, and have also been typed across the MalariaGEN data,
including the deletion at rs8176719 which determines AB/O
groups. The correlation between rs8176719 and neighbouring
SNPs is also shown in Figure 3. The pattern of association across
the cohorts is similar to those typically seen in studies of European
populations where the correlations between alleles at tag (marker)
SNPs and the causal allele are consistent across different samples.
The strongest meta-analysis signal at the locus is at rs8176722 with
P=8.9610210. Conditioning on rs8176719 also removes any
other signals of association (P.1024) from the region (Figure S6).
Bayesian analysis
The differences in ancestries of the three study samples can lead
to a causal SNP being differentially tagged, as observed at the HBB
locus in our data. As a consequence the effect sizes at directly
typed or imputed loci can vary between samples, even when the
risk at the causal locus is the same. Moreover, variation across
studies in imputation accuracy can also lead to differential levels of
effect size underestimation at SNPs not genotyped directly. These
effects are likely to be more important in studies across African
populations and motivate approaches which relax the assumption
of the same or ‘‘fixed’’ effect.
To investigate the impact of non-fixed effect approaches on the
evidence for association we used a normal approximation to the
logistic regression likelihood suggested by Wakefield [17]. One
way of thinking about the approach is that it uses the study-wise
estimated log-odds ratio (beta) and its standard error as summary
statistics of the data (See Text S2). For each model of association
we assume a prior on the log odds ratio which is normally
distributed around zero with a standard deviation of 0.2 (see [18]
for a discussion). By changing the prior on the covariance (or
correlation) in effect sizes between studies we can formally
compare models where:
1) The effects are independent across studies.
2) The effects are correlated equally between studies.
3) The effects are correlated, but to a greater degree
between Malawi and Kenya (referred to as ‘‘structured
effects’’ below).
4) The effects are the same across studies (referred to as
‘‘fixed effects’’ below).
(See Text S2 for details). For each model we can obtain a Bayes
factor (BF) for association by comparing it with the null model
where all the prior weight is on an effect size of zero. These models
are similar in spirit to those employed to look at shared effects
across sub-phenotypes (rather than populations) in a study of
ischemic stroke [19] or at heterogeneity between studies [20].
The genome-wide Bayes factors for the fixed effects and
structured effects models are plotted against each other in Figure 4.
From this plot we can see that the fixed effect BF is larger for SNPs
at ABO, while at HBB, there is more evidence for association when
effect sizes are allowed to vary more extensively between East and
West African collections (structured effects). The posterior
probability on each of the models at the SNPs in these regions is
shown in Figure S17. Similar results are seen when the prior on
the effect size is increased (standard deviation of 0.75; data not
shown).
Motivated by these observations at known malaria susceptibility
loci we performed a genome-wide scan (Figure 5) to look for
regions with strong evidence of association (log10(BF).4) under
model 2, 3 or 4 above. These are listed in Table S7. In large case-
control samples, like those analysed here, then for common SNP
(minor allele frequency .5%) the fixed effect meta-analysis P
values are highly correlated with the fixed effect BF (see Figure S7).
Nonetheless, power to detect new regions of association is highest
when the prior distribution of the effect sizes across cohorts is close
to the truth. We therefore advocate this approach as a way of
accounting for our uncertainty in the correct meta-analysis model
in terms of similarity of effect sizes between cohorts. Two regions
showing over twice as much evidence for association under the
structured effects model compared to the fixed effects model were
on chromosome 16 in the large gene CDH13, where the signal of
association is strongest in East Africa (Kenya and Malawi), and a
region of association on chromosome 14, where the association
signal is largely confined to West Africa (Gambia). The structured
effects log10(BF) for these regions is 4.84 and 4.03 respectively (see
Table S7).
GWAS of Severe Malaria across Africa
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Regional association test
Another possible approach to identifying genetic associations
across populations, where the most associated SNPs at a locus are
not necessarily the same, is to base a test on all SNPs within a
region [21,22]. One way to formulate this test is to consider the
causal SNP as a random effect, which is not observed, but is
assumed to have a correlation structure across individuals dictated
by the pattern of relatedness (or allele sharing) within the region of
interest. A test for association can then be constructed by asking
whether the random effect explains any of the covariance in the
phenotype (case-control status), after accounting for population
structure, which can be captured by including PCs as fixed effects
in the model (See Text S2). As the model includes only fixed effects
and a single additional random effect it can be computed using the
MMM software [11]. To assess the evidence for association we
used a score test statistic which has a complex, but computable,
distribution under the null to calculate a P value. We also
computed Bayes factors by specifying priors on the model
parameters, in particular on the proportion of the variance
explained by the region.
To exploit a region-based test we constructed allele sharing
matrices (as defined in [12]) for all SNPs within 50 kb of each of
approximately 20,000 genes in the genome (where there were at
least 5 SNPs in each cohort). We then tested for association as
described above to obtain a P value for each gene in each of the
three study collections using the filtered data sets. To check that
population structure was sufficiently accounted for by the inclusion
of five PCs, we calculated the genomic inflation factor of the P
values in each study and found them to all be less than 1.07 (after
removing HBB and ABO regions). We combined evidence across
cohorts using Fisher’s method [23]. The meta-analysis P values
had an acceptable genomic inflation factor of 1.071. See Figure
S8. We also multiplied Bayes factors across studies to obtain a
study-wide Bayes factor. We note that, unlike the fixed-effect SNP
analysis, these approaches to meta-analysis do not assume that the
same allele, or combination of alleles, determine susceptibility in
each cohort.
As a proof of principle we applied this test to all SNPs within the
HBB region (4.6 Mb to 5.5 Mb of chromosome 11), which covers
the two peaks of association in the single SNP analysis (Figure 3).
The region-based test showed evidence for association
(P,561025) in each cohort and had a meta-analysis
P=3.5610217, whereas the lowest SNPTEST meta-analysis P
value in the region (which also uses 5 PCs as covariates) is
5.7610213. Although this region would have been discovered via
either approach, this additional boost in power highlights the
potential benefit of region based tests.
In the gene-based analysis the most associated region was a gene
overlapping the region of strongest association at HBB in Malawi
and Gambia (OR51F1 from 4.73 Mb to 4.8.3 Mb, containing
Figure 3. Patterns of association around the HBB and ABO loci. In each figure the top three panels of the plot is the P value of the logistic
regression analysis using 5 PCAs in each cohort with the fixed-effect meta-analysis P value shown in the bottom panel. Circles represent genotyped SNP
and triangles imputed SNPs. SNPs in r2.0.2 with the functional SNPs in each region:rs334 in HBBwhich encodes the sickle locus [HbS], and rs8176719 in
ABO are coloured with yellow indicating more correlation and red indicating less. Vertical lines indicate the positions of the functional SNPs.
doi:10.1371/journal.pgen.1003509.g003
Figure 4. Comparison of fixed and structure effect Bayes factor at autosomal SNPs. Red dots indicate SNPs mapping to the HBB region in
and blue dots indicate those mapping to the ABO region (see Figure 3). Note that points below the diagonal line have more evidence for association
under a structured effects model, whereas those above the line have more evidence for association under a fixed effect model.
doi:10.1371/journal.pgen.1003509.g004
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approximately 70 SNPs), it had a meta-analysis P val-
ue = 4.4610211. In contrast the gene-based signal at the ABO
locus (P=1.661025) was significantly less than the SNP-based
analysis. It is likely that the inclusion of multiple SNPs from the
region and removal of assumptions about the direction of effect
across cohort reduces the signal of association at this locus.
However, the region-based analysis focuses attention on the
approximately 20,000 annotated genes; since consensus does not
yet exist on interpreting gene-based P values, BFs are useful in
evaluating the evidence for association in the gene-based tests. For
instance, if we assume that there are 20 annotated genes which
contain SNPs within 50 Kb that influence malaria susceptibility
then the prior odds of association are roughly 1 in 1000. In
comparison, the prior probability associated with any given SNP is
much lower, perhaps 1 in 100,000 [18]. Thus, a log10(BF) of 2
(BF= 100) for the region-based analysis gives the same posterior
probability of association to a log10(BF) of 4 in the single-SNP
analysis. Plots of the empirical distribution of the estimated
proportion of the phenotypic variance explained by the regions,
and a comparison of Bayesian and frequentist tests, are shown in
Figure S19.
Outside the ABO and HBB regions, five regions contained genes
with BF greater than 100. Although this analysis is gene focussed, it
does not necessarily directly implicate specific genes but regions of
the genome (see Table S7), but here we refer by gene name to the
regions with the most evidence. These include the regions of the
genes BET1L (telomere chromosome 1, log10(BF)= 2.504),
C10orf57 (chromosome 10, log10(BF) = 2.387), MYOT (chromo-
some 5, log10(BF)= 2.051)), SMARCA5 (chromosome 4,
log10(BF)= 2.04) and ATP2B4 (chromosome 1, log10(BF)= 2.015).
Interestingly, we note that the SMARCA5 region is 250 kb upstream
of the GYPE/A/B gene cluster which encodes the M blood group
antigens, and that the variants in the BET1L gene have been
associated with platelet volume in Europeans [24,25]. A recent
study [26] identified malaria-associated variants in ATP2B4.
Another benefit of a test which averages over SNPs within a
region to obtain a single P value or BF is that it is possible to look
for consistent association in collections of genes (or regions) of
interest. We hypothesised that loci either previously implicated in
auto-immune disease [27] (referred to below as ‘‘Immunochip
regions’’), associated with measurable properties of red and white
blood cells and platelets [24,28,29], or known determinants of
blood groups (obtained from the HUGO database and excluding
the ABO types) might be candidates for malaria susceptibility
variants. To investigate, we also calculated region-based Bayes
factors for these regions and ranked them against the results from
the gene-based analysis. Table S8 shows that only the Immu-
nochip loci showed a nominally significant (P=0.001) excess of
high-ranking BFs (those in the top 5% of the empirical
distribution) of genes. We note that, other than the BET1L locus,
the two highest ranking (in the top 0.1% of the empirical
distribution) regions include the RUNX3 locus, implicated in
ankylosing spondylitis [30] (empirical P=0.0060) and the region
containing the IL12A gene (empirical P=0.0096) implicated in
Celiac disease [31] and multiple sclerosis [31,32].
Simulations
The empirical observations described above, including the
heterogeneity of signal at the HBB locus, and the ability of the
region-based test to detect the recently identified association at the
ATP2B4 locus [26], motivates further investigation of the new
approaches to association analysis. To further assess the utility of
these methods we used HAPGEN [33,34] to generate a series of
simulated case-control meta-analysis datasets in ten randomly
chosen genomic regions, using samples from three African
populations collected as part of the HapMap project. We
conducted two sets of simulation, designed to test two distinct
association scenarios (see Methods). In the first set, the three
populations were assigned the same underlying causal variant
(with an odds ratios of 1.2 per allele), but the causal variant was
Figure 5. Evidence for association at approximately 1.3M autosomal SNPs. The plot shows the log10 Bayes factor comparing the structured
effects model (model 4; see main text) to a model of no association. Chromosomes are coloured alternatively light and dark blue. The horizontal line
indicates regions with strong evidence of association (BF.1e4).
doi:10.1371/journal.pgen.1003509.g005
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assumed to be untyped. In the second set, each of the three
populations had a different causal variant. We also carried out a
series of null simulations (with no causal variants present at all) in
order to quantify false-positive rates. We ranked all the simulations
according to either the strongest evidence of association under
different single SNP analyses or the region-based approach, and
plotted true positive and false positive rates for all methods (Figure
S18). We found that if the causal SNP is the same across
populations then the fixed effect approaches, and Bayesian
approaches that assume highly correlated effects, perform best.
In contrast, when the causal SNP is population-specific the region-
based approaches have the highest power for a fixed false positive
rate. Importantly, the single SNP correlated effects Bayesian
approach performs well under both scenarios, highlighting the
utility of this approach when the assumption of homogeneous
effect sizes across populations does not hold.
Discussion
The purpose of our analysis was to assess the utility of
imputation based meta-analysis for combining data from individ-
uals, typed on different genotyping arrays, and sampled from
different African populations, for studying Malaria susceptibility.
Until recently [26], no single genome-wide analysis of malaria has
revealed evidence of association strong enough to overcome the
implicit low prior probability that any given SNP affects
susceptibility. We show that by increasing sample size, through
meta-analysis, it is possible to identify such polymorphism from
diverse African populations. This reinforces the utility of applying
the GWAS approach in this setting.
The two loci we identified with P values,561028 have been
known to influence malaria susceptibility for more than 25 years
and are likely to exhibit some of the strongest effects on risk for
common alleles. Extensive analysis of other phenotypes, both
communicable and non-communicable, suggests that these loci are
the tip of the iceberg, with many smaller effects left to be found.
Identifying these regions requires additional statistical power.
Primarily this can be achieved by increasing the size of the data
sets by collecting more individuals or obtaining data at a denser set
of SNPs, perhaps initially through imputation [6], but ultimately
by whole-genome sequencing of study individuals. By typing more
SNPs the difference in patterns of linkage disequilibrium between
different ancestral groups, which can complicate analysis, may be
mitigated as it becomes more likely that the causal variant is typed
directly. Nonetheless, a combination of approaches such as the
Bayesian random effect models and region-based tests outlined
here may still provide additional power by relaxing the assump-
tions of standard SNP-by-SNP fixed effect analysis. For example,
when the genetic effects are modified by the environment (such as
the parasite or mosquito sub-species), or the clinical criteria for
inclusion as a case individual varies between cohorts, or when
different mutations arise at the same locus in different ancestral
populations, even typing the causal variant may still result in effect
heterogeneity. We note that the application of these new methods
requires additional care because they are potentially less robust to
sporadic genotyping errors in one or more cohorts. The ultimate
decision about which of the approaches we have explored will be
most appropriate for other researchers working on GWAS in
complex populations will depend on the circumstances of
individual studies. We view comparison of the models to be
informative, and suggest averaging across models where a single
summary of the evidence for association is preferable. Prior
information on the likelihood of real, or apparent, effect
heterogeneity can easily be incorporated in this approach.
Although the methods described in this paper do not confidently
identify any new malaria susceptibility loci, they do highlight a set
of potential candidates. For example, variation in the large gene
CDH13 has recently been conclusively associated with adiponectin
levels [35] and other metabolic traits [36]. The chromosome 4
gene-based association may further implicate glycophorins A, B
and E which encode the M blood group antigens and are potential
receptors for the malaria parasite P. falciparum. The signal of
association at ATP2BA coincides with the findings of a recent
GWAS study in Ghana [26] and is of potential functional
significance as it encodes the major calcium-transporting ATPase
on the erythrocyte plasma membrane. It is also just upstream of
LAX1, a transmembrane protein expressed in peripheral blood
lymphocytes and implicated in T and B cell responsiveness to
stimulation [37]. Further data will be required to confirm if these
replicate in other collections, which specific genes are involved,
and how genetic variation in the region influences severe malaria
susceptibility.
There has been a long standing hypothesis that high mortality
from infectious disease in ancestral populations has led to selection
pressures which have had an impact on human physiology. For the
first time in human genetics we are in a position to test such
hypotheses. The random effects models and the region-based test
described here provide a statistically principled approach to
looking systematically for shared, antagonistic or pleiotrophic
effects across phenotypes. The identification of new malaria
susceptibility loci that will result from larger studies will empower
investigations of this kind as well as providing desperately needed




The studies and sample sets described in this manuscript form
part of a larger ongoing project within the Malaria Genomic
Epidemiology Network (www.malariagen.net). Here we describe
partner projects from the MRC laboratories in Fajara, Gambia,
The KEMRI-Wellcome Trust Unit in Kilif, Kenya and The
Blantyre-Wellcome Trust Project in Blantyre, Malawi (Table S1).
At each study site, cases of severe malaria were recruited on
admission to hospital while controls (cord blood samples) for the
cases were sampled from the same populations by recruiting
mothers giving birth at local maternity units. This was usually
done as part of a larger programme of clinical research on malaria,
designed and led by local investigators. Further details can be
found by visiting the MalariaGEN website (www.malariagen.net).
We define a case of severe malaria as an individual admitted to a
hospital or clinic with P. falciparum parasites in the blood film and
with clinical features of severe malaria as defined by WHO criteria
[38,39].
Ethics statement
Study sites worked with the MalariaGEN resource centre to
define best practices for ethical conduct of these genetic studies in
the local setting, including the development of guidelines for
obtaining informed consent [40–42]. Further information on
policies, research and the consent process may be found on the
MalariaGEN website (http://www.malariagen.net/community/
ethics-governance). All research was reviewed and approvals
granted by local Research Boards and Ethics committees in The
Gambia: The Gambia Government/MRC Unit Joint Ethics
Committee (SCC1029 and SCC670/630); Kenya: Research Ethics
Committee from the KEMRI-Wellcome Research Programme,
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Kilifi, Kenya (SCC1192); Malawi: College of Medicine Research
Ethics committee, University of Malawi and the Blantyre Malaria
Project with the Malawi-Liverpool-Wellcome Trust Programme,
Blantyre, Malawi (P.05/06/422) and Oxford; Oxford University
Tropical Research Ethics committee (OXTREC), Oxford, United
Kingdom (OXTREC 020-006). This paper is published with the
permission of the Director of KEMRI.
DNA extraction and genotyping
Sample collection and DNA extraction were undertaken at
partner study sites and at the MalariaGEN Resource Centre as
previously described [4]. All samples submitted to the Malaria-
GEN Resource Centre underwent a standard set of procedures
that included quantification using picogreen, genotyping of 65
polymorphisms (including HbS - rs334, and 3 gender-typing SNPs)
on the Sequenom iPLEX MassArray platform and matching to
baseline clinical data (e,g gender, ethnic group and case-control
status) as described in [4]. Samples meeting DNA concentration
and genotyping criteria with appropriate clinical data were
selected for GWAS. However, due to restrictions on the total
amounts of blood and DNA collected, it was necessary to first
whole-genome amplify all gDNA samples by multiple-displace-
ment-amplification as previously described [10]. Briefly gDNA
was whole-genome amplified using the REPLI-g kit (Qiagen,
Crawley, UK) with the modification for increased sample
volumes). All final reaction DNA concentrations were measured
using PicoGreen reagent (Invitrogen, Paisley, UK) and adjusted to
100 ng/ul with low TE (10 mM Tris-HCL pH 8, 0.1 mM EDTA-
Na2).
Twelve percent of samples were assessed for amplicon size
range using the Agilent 2100 bioanalyser (Agilent Technologies,
Stockport, UK) according to manufacturer’s instructions and for
genotyping efficiency using the SNP set described above. Whole-
genome amplified material was submitted to the Wellcome Trust
Sanger Institute for genotyping on as part of the ongoing
MalariaGEN consortial Project 1 (http://www.malariagen.net/
node/128). Details of the 3 datasets are described in Table S1.
Data processing
Our processing pipeline first uses the AutoConvert function in
Illumina Beeline software to convert raw read data from Illumina
BeadArray (idat) files into binary genotype call (gtc) files using
cluster positions and normalisation information in the (egt) files.
We used the gtc files to extract the calls made by the algorithm
GenCall [5], to extract the raw intensities for GenoSNP [6] and
the normalised intensities for the program Illuminus [7]. We wrote
custom software to split the data into chunks, and modified
Illuminus and GenoSNP to accept the new format. This allowed
us to parallelise the genotype calling. We then included all the
three sets of genotypes, along with normalised intensity data into a
single vcf file (see http://www.1000genomes.org/node/101).
Genotype calling
Three genotype calling algorithms were specifically chosen to
utilise different information in the intensity data; GenoSNP which
independently calls genotypes in each individual by clustering
probe intensities across SNPs; Illuminus which independently calls
genotypes at each SNP by clustering probe intensities across study
individuals; and Gencall which uses predetermined probe intensity
information to infer genotypes at each SNP in each individual.
Each of the three algorithms can make one of four calls for a
given individual at a given SNP: 0,1,2 or missing. To merge the
calls we took a simple consensus approach to generate a single call
for each genotype. The rules were as follows:
N If less than two algorithms were confident enough to make a
call (and reported the genotype as missing) we labelled the
genotype as missing.
N If all algorithms that made a call agreed we kept the inferred
genotype.
N If there were any discordance between the calls we labelled the
genotype as missing.
The above rule is strict in the sense that only complete
agreement between algorithms that made a call leads to a
genotype call in the merged data. Analysis of trio data
demonstrated that this retains a relatively high fraction of calls
relative to anyone calling approach and had the lowest number of
Mendelian errors in terms of absolute errors made and the fraction
of SNPs with one or more errors (data not shown).
Quality control
Prior to imputation we applied quality control (QC) metrics to
each cohort as follows. All QC was performed on the ‘‘consensus’’
genotype call, as defined above. First, we aligned each dataset to
the forward strand of the reference genome using the Illumina-
supplied chip manifest, and restricted attention to the set of SNPs
in the HapMap 3 reference panel (obtained from the IMPUTE
website). We excluded samples with missingness .10% or
heterozygosity outside the range 0.25–0.35. We then proceeded
to filter out SNPs based on missingness (or discordance of the
consensus genotype call), minor allele frequency, and HWE P
value. We also examined differential missingness between cases
and controls in each cohort, but did not apply exclusions based on
this criterion. Next, we computed pair-wise concordance between
samples using a thinned set of approximately 20,000 SNPs chosen
to be no closer than 100 kb apart. For each pair of highly
concordant samples we removed the sample with higher missing-
ness.
Genotype imputation
Imputation was performed with IMPUTE 2.12, using the
phased release #2 of HapMap3 from the Impute website (http://
mathgen.stats.ox.ac.uk/impute/). All HapMap3 haplotypes from
all populations (African and non-African) were used. The genome
was split up into segments which are either 5 Mb, or have 20 000
reference SNPs (whichever is smaller), with an additional 500 kb
buffer on either side of the segment. We used imputation
parameter settings of k = 80 and Ne= 14000. Imputation was
performed in parallel for each segment, and segments were
reconstructed into chromosomes once all imputations had
finished. For each cohort we examined diagnostic metrics to
assess imputation performance (see Figure S11).
Accuracy of imputation was measured using IMPUTE2’s ‘‘type 2
r2’’, which is the squared correlation coefficient between actual
genotypes in our GWAS dataset (discrete values of 0, 1, or 2 measured
by the genotyping algorithms described above) and the expected
genotype, or ‘‘dosage’’, predicted by IMPUTE2 (a continuous value
from 0–2). As long as variants present in the GWAS are not biased
towards being easier or more difficult to impute than typical variants
in HapMap3, this metric is a good representation of the accuracy of
our imputed genotypes at all sites [5].
Principal component analysis and filtered data set
To investigate population structure, and for genome-wide scans
performed using SNPTEST and other tools that do not directly
model relatedness, we further restricted the set of individuals as
follows. For each cohort we computed a matrix (denoted R) of
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genome-wide allele sharing, using approximately 100,000 SNPs
thinned to be at least 0.01 cM apart using the HapMap combined
recombination map. Using this matrix we excluded one of each
pair of individuals that were closely related. Using the same matrix
R we also computed the projection of samples onto the principal
components (given by the eigenvectors of R). To investigate the
potential for population structure to generate false signals of
association we calculated the correlation between each PC and
case control status using logistic regression. The resulting P values
are shown in Table S4 and show that case control status is
significantly associated with the principal components.
To ensure individuals of unusual ancestry did not dominate
analyses, we iteratively excluded individuals that were extreme
outliers (.10 standard deviations away from the mean) in any of
the first ten PCA components, and re-computed PCs; this resulted
in a small number of further exclusions (see Table S5). Projections
of samples onto the principal components are depicted in Figure 2
and Figures S14, S15, S16.
Statistical analysis
Relatedness matrix and PCA computations were performed
using QCTOOL (http://www.well.ox.ac.uk/,gav/qctool) and
the generateR program included with the MMM program [12] .
Association tests were performed using SNPTEST v2.3.0, using
maximum likelihood estimation taking into account uncertainty in
imputed genotypes, and including 5 PCAs to control for
population structure. Mixed model scans and region based tests
were performed using MMM, with mean-centering of genotypes,
imputation of missing and uncertain genotypes. For region-based
tests we computed relatedness matrices using all SNPs within the
region that passed QC filters (info.0.75, MAF.0.001) and used
this relatedness matrix as a random effect in the MMM program.
Five PCs were included to control for population structure. For
Bayesian tests, we specified the prior on the h parameter (see Text
S2) as a beta distribution with parameters 1.5 and 100; intuitively
this corresponds to a belief that the regional relatedness matrix
explains relatively little (around 1%) of the overall residual
variance. Pairwise LD computations were performed using
QCTOOL, which uses the EM algorithm to estimate the phase
of individuals heterozygous at both markers. Meta-analysis was
performed using fixed-effect inverse variance weighting and
Fisher’s method using custom software written in C and R [43].
Bayes factors for meta-analysis models were also calculated in R.
For technical details on novel methods see Text S2.
Region definitions
For the gene based analysis regions were obtained by taking the
transcript start and end positions from the refGene table of the
UCSC genome browser database [44]; where a gene had multiple
transcripts we used the longest transcript. This resulted in 22903
gene regions, of which 21908 were on autosomes. We then added
50 kb to start and the each end of the region before applying the
regional association test and only included regions with more than
5 SNPs in each of the three cohorts.
For empirical investigation of regional association test statistics
we used several lists of regions. A list of blood group antigen genes
was obtained from the HUGO Gene Nomenclature Committee
website (http://www.genenames.org/genefamilies/blood-group)
and these were extracted from the gene based analysis described
above by matching gene names. To define lists of genes associated
with blood cell phenotypes, we took association signals from [28]
(red blood cell traits comprising Hemoglobin concentration (Hgb),
hematocrit (Hct), mean corpuscular volume (MCV), mean
corpuscular hemoglobin (MCH), mean corpuscular hemoglobin
concentration (MCHC) and red blood cell count (RBC)) [24],
(platelet traits comprising mean platelet volume (MPV) and/or
platelet count (PLT)), and [29] (white blood cell traits comprising
total white blood cell count (WBC), and counts of Neutrophils,
Basophils, Lymphocytes and Monocytes.) For each of the three
overall phenotypes (red or white blood cell, or platelet traits) we
recorded the most-associated SNP across sub-phenotypes for each
reported locus from the relevant study. For each such locus, we
then defined a region by finding the furthest SNP upstream and
downstream of the locus having r2.0.5 with the associated SNP,
and then moving out to the nearest recombination hotspot. If the
region contained no genes we further extended it by 25 kb in each
direction. This procedure is the same as those implemented in
GRAIL [45]. To define a list of regions associated with auto-
immune disorders we used fine-mapping regions from the
Immunochip platform [27].
Simulations of effect heterogeneity
Ten 100 Kb regions were chosen uniformly from across the
autosomal genome. For each region we used the program
HAPGEN (v2.1.2, with default settings used [34]) to simulate a
total of 1,000 meta-analysis datasets, each consisting of 1000 cases
and 1000 controls from each of the three African populations
(YRI, LWK and MKK) from HapMap3 (release 2). We repeated
this simulation under three scenarios of association for a total of
30,000 datasets. The scenarios considered were:
1. (Null simulations): all variants were simulated under the null
model of no association (and thus cases and controls were
drawn from the same distribution.)
2. (Single-variant simulations): A single causal variant was picked
in the region and the three populations were simulated
assuming this causal variant.
3. (Three-variant simulations): A different causal variant was
chosen for each population.
Causal variants were picked at random from among those with
combined MAF.0.05, and assumed to act additively on the log
odds scale, with odds ratio of 1.2.
For each dataset we tested each SNP in the region for
association, separately in each population, using SNPTEST. We
combined effect size estimates and standard errors across
populations using frequentist fixed-effect and Bayesian meta-
analyses (Methods and Text S2). For Bayesian meta-analysis, prior
variance on effect sizes was set to 0.22 and we used between-
population prior correlations of 1 (fixed effect), 0.9, 0.5, and 0
(independent effect). For the single causal variant scenario, the
chosen causal variant was masked from association testing.
For each dataset and population we also computed a Pvalue and
Bayes factor for the regional association test (Methods and Text
S2). For the single causal variant scenario, the causal variant was
masked from computation of the covariance matrix. We combined
P values using Fisher meta-analysis and multiplied Bayes factors
across populations to produce a single P value and a single Bayes
factor for the dataset.
For each of the two scenarios of association and each method of
detecting association across the region (regional test with Fisher
meta-analysis, regional test with Bayesian meta-analysis, best
single-SNP frequentist meta-analysis, best single-SNP Bayes factor
for each of the four choices of correlation parameter) we produced
ROC curves (Figure S18) by combining all datasets simulated
under that scenario and the null scenario, ranking by the chosen P
value or Bayes factor, and computing empirical true and false
positive rates.
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Data access
For information on access to project data see www.malariagen.net.
Supporting Information
Figure S1 Example of cluster plot from Malawi cohort with
outlying sets of individuals.
(TIF)
Figure S2 Distribution of relatedness between most-related pairs.
(TIF)
Figure S3 Comparison of logistic regression (SNPTEST) and
mixed model (MMM) P values.
(TIF)
Figure S4 SNPs showing highly divergent P values between
logistic regression and mixed model scans.
(TIF)
Figure S5 –log10(P values) for test of association using the mixed
model.
(TIF)
Figure S6 Top: signal of association in the HBB region after
conditioning on the genotype at the known causal locus rs334.
Bottom: signal of association in the ABO region after conditioning
on the genotype at rs8176719.
(TIF)
Figure S7 Comparison of meta-analysis P values versus Bayes
factors under the fixed-effect model.
(TIF)
Figure S8 Quantile-quantile plots of the region-based test in the
three cohort and in the meta-analysis. The genomic control
inflation factor is given in the title of the plots.
(TIF)
Figure S9 Manhattan plot showing –log10 P values (thresholded
at 10) for additive, dominant, heterozygote, recessive, and general
models, and additive model conditional on the genotype at the
sickle locus rs334, across all imputed SNPs. Meta-analysis P values
for all three cohorts and for the East African cohorts are also
shown for additive, dominant, recessive and heterozygote scans.
(TIF)
Figure S10 Manhattan plot showing –log10 P values (thre-
sholded at 10) for additive, dominant, heterozygote, recessive, and
general models, and additive model conditional on the genotype at
the sickle locus rs334, across all non-excluded genotyped SNPs.
Meta-analysis P values for all three cohorts and for the East
African cohorts are also shown for additive, dominant, recessive
and heterozygote scans.
(TIF)
Figure S11 Example output from the imputation quality control
pipeline for the Kenya imputation. a) per-SNP certainty (mean
maximum posterior genotype call); b) per-SNP accuracy (type2 r2);
c) per-individual type2 r2, averaged across segments; d) per-
segment heterozygous call accuracy (proportion of true heterozy-
gous calls that are correctly imputed with high certainty); e)
average per-SNP type2 r2, computed per segment and plotted
against the position of the segment.
(TIF)
Figure S12 The distribution of imputation quality (measured by
type2 r2) across imputed Kenyan samples. The red line is at
r2 = 0.909, and is the minimum between the two peaks.
(TIF)
Figure S13 The distribution of ethnic groups in Kenyan samples
that were imputed with higher or lower quality (as defined by the
red line in Figure S12). The difference in the two distributions is
highly significant (Fisher’s exact test, P=461024), suggesting that
ethnic differences contribute to the bimodal distribution of
imputation quality seen in Figure S12.
(TIF)
Figure S14 Population-specific PCA analysis of Gambian samples.
(TIF)
Figure S15 Population-specific PCA analysis of Kenyan samples.
(TIF)
Figure S16 Population-specific PCA analysis of Malawian samples.
(TIF)
Figure S17 Comparison of fixed, structured, correlated and
independent-effect models at the ABO and HBB loci. The height
of each bar represents the posterior probability that the
corresponding model is true, under the assumption that one of
the models is true.
(TIF)
Figure S18 ROC curve showing empirical true positive rate (y-
axis) against false positive rate (x-axis) for each method used to
detect regional association (regional test with Fisher meta-analysis,
regional test with Bayesian meta-analysis, best single-SNP
frequentist meta-analysis in region, best single-SNP Bayes factor
for each of the four choices of correlation parameter) under the
single- variant association scenario (left) and the three-variant
association scenario (right).
(TIF)
Figure S19 a) Empirical distribution, across approximately
20,000 gene regions, of the maximum likelihood estimate of the
eta parameter (see Text S2), for the region-based test. Overlaid
(red line) is the assumed prior distribution under the alternative
used to calculate Bayes factors in the region-based analysis. b)
Scatter plot of the log10 combined Bayes Factor and the -
log10(Fisher’s P value). Dotted horizontal and vertical line
indicates log10(Bayes Factor) = 2 and a -log10(P value) = 0.0005.
(TIF)
Table S1 Details on the 3 study sites and genotyping platforms.
(DOCX)
Table S2 Pre-imputation individual QC.
(DOCX)
Table S3 Pre-imputation SNP QC.
(DOCX)
Table S4 P values for correlation between the first 5 PCs and
case/control status.
(DOCX)
Table S5 Post-imputation sample exclusions.
(DOCX)
Table S6 Genomic Inflation factors (l) for logistic regression
and mixed-model scans.
(DOCX)
Table S7 Regions showing most association in single-SNP and
regional association test analyses.
(XLSX)
Table S8 Enrichment of low region based test P values in three
previously defined sets of regions. Each P value in the table results
from a one-sided binomial test for an enrichment in the number of
regions with empirical P value below the given threshold. The
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bottom row gives a summary of the distribution of the number of
SNPs in each region. Note that the Immunochip regions contain
on average more SNPs than the gene-based analysis (median= 66
(quartiles = 52, 92)) from which the empirical P value is calculated.
(DOCX)
Text S1 Details of quality control.
(DOCX)
Text S2 Supplementary statistical details.
(PDF)
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